Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.
"Both donanemab and Leqembi are lab-made antibodies, administered by IV, that target one Alzheimer’s culprit, sticky amyloid buildup in the brain. And both drugs come with a serious safety concern — brain swelling or bleeding that in the Lilly study was linked to three deaths."